A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia

• ClinicalTrials.gov Identifier: NCT02880462
• Recruitment Status: Completed
• First Posted: August 26, 2016
• Last Update Posted: March 24, 2020
• Sponsor: Central South University
• Collaborator: Stanley Medical Research Institute
• Information provided by (Responsible Party): Renrong Wu, Central South University

Study Description

Brief Summary:

The goal of the study is to investigate whether adding different doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.

This study will compare the sulforaphane with placebo. There is a thirty percent change (less than half) of receiving the placebo. The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.

Condition or disease	Intervention/treatment	Phase
Schizophrenia	Dietary Supplement: sulforaphane; Other: placebo	Phase 2

Detailed Description:

This study will be carried out in six mental health institutes in China and total of 180 patients with first-episode or early onset schizophrenia will be enrolled into the study. The mental health institute at the Second Xiangya Hospital, Central South University.

Individuals who participate in the study will be followed for 24 weeks. The changes in clinical symptoms and neurocognitive function will be assessed from baseline (week-2) to week-6 (acute phase), and week-12 to week-24 (maintenance phase).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 172 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: Participants and researchers are blind to treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan.
• Primary Purpose: Treatment
• Official Title: Phase 2 Study of the Effect of add-on Sulforaphane in Treatment of Schizophrenia
• Actual Study Start Date: December 26, 2016
• Actual Primary Completion Date: May 20, 2019
• Actual Study Completion Date: May 20, 2019

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: high dose sulforaphane; The goal of the study is to investigate whether adding high doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.	Dietary Supplement: sulforaphane; Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.; Other Name: Nutramax
Active Comparator: low dose sulforaphane; The goal of the study is to investigate whether adding low doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.	Dietary Supplement: sulforaphane; Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.; Other Name: Nutramax
Placebo Comparator: placebo; The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.	Other: placebo; Placebo is made of starch

Outcome Measures

Primary Outcome Measures :

1. Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score [ Time Frame: 24 weeks ]
   The investigators will use the MATRICS Consensus Cognitive Battery (MCCB) Composite score as primary cognitive outcome measure.

Secondary Outcome Measures :

1. side effects by SAFTEE [ Time Frame: 24 weeks ]
   The investigators will evaluate side effect by The Systematic Assessment for Treatment Emergent Events (SAFTEE).
2. side effects by AIMS [ Time Frame: 24 weeks ]
   The investigators will evaluate side effect by Abnormal Involuntary Movement Scale (AIMS)
3. side effects by BAS [ Time Frame: 24 weeks ]
   The investigators will evaluate side effect by Barnes Akathisia Rating Scale (BAS).
4. side effects by SAS [ Time Frame: 24 weeks ]
   The investigators will evaluate side effect bySimpson-Angus Scale (SAS).
5. Change of clinical symptoms by PANSS [ Time Frame: 24 weeks ]
   The change of Positive And Negative Syndrome Scale (PANSS) total, positive and negative symptoms before and after treatment at different follow up point
6. Change of clinical symptoms of CGI [ Time Frame: 24 weeks ]
   The change of Clinical Global Impression (CGI) before and after treatment at different follow up point

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Meet The Diagnostic and Statistical Manual (DSM-V) diagnostic criteria for schizophrenia
2. First onset or duration of illness less than 3 years with current symptoms exacerbation
3. Hospitalized in an acute episode (first hospitalization), or subsequent hospitalization or acute relapse)
4. Male and female with aged 18 to 50 years
5. PANSS total >=75 at 2 weeks. .
6. Signed the study consent for participation

Exclusion Criteria:

1. having history of substance dependence or abuse or whose symptoms are caused by the other diagnosable mental disorders;
2. having history of traumatic brain injury, seizures or other known neurological or organic diseases of the central nervous system;
3. taking antidepressants, stimulants, mood stabilizer or accepts electricity shock treatment;
4. having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be manage in an inpatient setting;
5. the routine blood tests showing abnormal renal, liver function or other metabolic results .
6. pregnant or lactating women

Contacts and Locations

Sponsors and Collaborators

Central South University

Stanley Medical Research Institute

Investigators

• Principal Investigator: Jianjun Ou, M.D Ph.D; Central South University
• Principal Investigator: Renrong Wu, M.D Ph.D; Central South University
• Study Chair: Jingping Zhao, M.D Ph.D; Central South University
• Principal Investigator: Hua Jin, M.D Ph.D; University of California, San Diego

More Information

Publications:

Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord. 2004 Jun;80(2-3):249-56. doi: 10.1016/S0165-0327(03)00135-6.

Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011 Jan;35(3):878-93. doi: 10.1016/j.neubiorev.2010.10.008. Epub 2010 Oct 23.

• Responsible Party: Renrong Wu, Professor, Central South University
• ClinicalTrials.gov Identifier: NCT02880462
• Other Study ID Numbers: Stanley-Sulforaphane
• First Posted: August 26, 2016
• Last Update Posted: March 24, 2020
• Last Verified: March 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Renrong Wu, Central South University:

schizophrenia; sulforaphane

Additional relevant MeSH terms:

Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Sulforaphane; Anticarcinogenic Agents; Protective Agents; Physiological Effects of Drugs; Antineoplastic Agents